NASDAQ: XLOXilio Therapeutics Inc Stock
$1.04+0.00 (+0%)
Updated Apr 30, 2024
XLO Price
$1.04
Fair Value Price
$1.17
Market Cap
$35.85M
52 Week Low
$0.49
52 Week High
$3.25
P/E
-0.37x
P/B
0.97x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$76.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.65
Operating Cash Flow
-$69M
Beta
1.01
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XLO Overview
Xilio Therapeutics Incorporated is a biotech company that develops immunotherapies for cancer patients. Its inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XLO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XLO ($1.04) is undervalued by 11.06% relative to our estimate of its Fair Value price of $1.17 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XLO ($1.04) is not significantly undervalued (11.06%) relative to our estimate of its Fair Value price of $1.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XLO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XLO due diligence checks available for Premium users.
Be the first to know about important XLO news, forecast changes, insider trades & much more!
XLO News
Valuation
XLO fair value
Fair Value of XLO stock based on Discounted Cash Flow (DCF)
Price
$1.04
Fair Value
$1.17
Undervalued by
11.06%
XLO ($1.04) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XLO ($1.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XLO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XLO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.37x
Industry
14.91x
Market
40.82x
XLO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.97x
Industry
5.89x
XLO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XLO's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.7M
Profit Margin
0%
XLO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$60.9M
Liabilities
$24.1M
Debt to equity
0.65
XLO's short-term assets ($48.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XLO's short-term assets ($48.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XLO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.4M
Investing
$0.0
Financing
-$1.6M
XLO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XLO vs Biotech Stocks
Xilio Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.